Jia Jie Biomedical Co., Ltd.

As of June 30, 2026, Jia Jie Biomedical Co., Ltd. carries a market capitalization of 1.34B, placing it among publicly traded companies globally. Its enterprise value stands at 964.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Jia Jie Biomedical Co., Ltd. has 118.74M shares outstanding.

As of June 30, 2026, Jia Jie Biomedical Co., Ltd. trades at a trailing price-to-earnings ratio of 433.24. The price-to-sales ratio is 2.60, and the price-to-book ratio stands at 0.83.

As of June 30, 2026, Jia Jie Biomedical Co., Ltd. trades at an EV/EBITDA multiple of 112.56 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 964.60M versus a market cap of 1.34B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jia Jie Biomedical Co., Ltd. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.59, indicating elevated leverage, while an interest coverage ratio of 8.05 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jia Jie Biomedical Co., Ltd. posted a return on equity (ROE) of 0.19, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.17, measuring how efficiently the asset base is converted into earnings. The company generates approximately 8.23M in revenue per employee across its workforce of 62.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.68 indicates how many times Jia Jie Biomedical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jia Jie Biomedical Co., Ltd. recorded an income tax benefit of -924,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 2.73M, leaving 3.09M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Jia Jie Biomedical Co., Ltd.'s stock has declined approximately 29.35% over the past 52 weeks. The 50-day moving average sits at 11.10, while the 200-day moving average is 12.30.

Over the twelve months ended June 30, 2026, Jia Jie Biomedical Co., Ltd. generated 514.65M in revenue and converted that into 3.09M in net income, yielding earnings per share of 0.03. EBITDA reached 8.57M, while operating income came in at -11.51M.

As of June 30, 2026, Jia Jie Biomedical Co., Ltd. holds 500.33M in cash and equivalents against 92.53M in total debt, resulting in a net debt position of -150.53M. Total book value stands at 1.62B, with working capital of 439.21M providing operational flexibility.

Jia Jie Biomedical Co., Ltd. produced 13.04M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -65.39M in capital expenditures, free cash flow totaled -52.35M - equivalent to -0.44 per share.

Over the twelve months ended June 30, 2026, Jia Jie Biomedical Co., Ltd. posted a gross margin of 26.95, reflecting its pricing power and cost economics. The operating margin of -2.24 and net profit margin of 0.60 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.14, meaning Jia Jie Biomedical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Jia Jie Biomedical Co., Ltd.'s most recent stock split took place on January 2, 2025 with a 760:781 split ratio.

As of June 30, 2026, Jia Jie Biomedical Co., Ltd. has an Altman Z-Score of 4.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.